Updates of prostate cancer staging: Prostatespecific membrane antigen

Niranjan J. Sathianathen, Alastair Lamb, Rajesh Nair, Nicolas Geurts, Catherine Mitchell, Nathan L. Lawrentschuk, Daniel A. Moon, Declan G. Murphy

Research output: Contribution to journalReview article

5 Scopus citations

Abstract

The ability to accurately stage prostate cancer in both the primary and secondary staging setting can have a major impact on management. Until recently radiological staging has relied on computer tomography, magnetic resonance imaging, and nuclear bone scans to evaluate the extent of disease. However, the utility of these imaging technologies has been limited by their sensitivity and specificity especially in detecting early recurrence. Functional imaging using positron-emission tomography with a radiolabeled ligand targeted to prostate-specific membrane antigen has transformed the prostate cancer imaging landscape. Initial results suggest that it is a substantial improvement over conventional imaging in the setting of recurrence following primary therapy by having a superior ability to detect disease and to do so at an earlier stage. Additionally, it appears that the benefits seen in the secondary staging setting may also exist in the primary staging setting.

Original languageEnglish (US)
Pages (from-to)S147-S154
JournalInvestigative and Clinical Urology
Volume57
DOIs
StatePublished - Jan 1 2016

Keywords

  • Local neoplasm recurrence
  • Positron-emission tomography
  • Prostatic neoplasms
  • X-ray computed tomography

Fingerprint Dive into the research topics of 'Updates of prostate cancer staging: Prostatespecific membrane antigen'. Together they form a unique fingerprint.

  • Cite this

    Sathianathen, N. J., Lamb, A., Nair, R., Geurts, N., Mitchell, C., Lawrentschuk, N. L., Moon, D. A., & Murphy, D. G. (2016). Updates of prostate cancer staging: Prostatespecific membrane antigen. Investigative and Clinical Urology, 57, S147-S154. https://doi.org/10.4111/icu.2016.57.S2.S147